A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood

Hematological Oncology

Volumn 24, Issue 4, 2006, Pages 227-233

  Poodt, J ^a   Fijnheer, R ^a   Walsh, I B B ^a   Hermans, M H A ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Blood; JAK2; Myeloproliferative; Real time PCR; V617F

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DNA DETERMINATION; HUMAN; INTERMETHOD COMPARISON; MYELOID METAPLASIA; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUTATION, MISSENSE; MYELOFIBROSIS; POLYCYTHEMIA VERA; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 33845950539     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.800     Document Type: Article

References (18)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
2. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004; 41: 1-5.
3. el-Kassar N, Hetet G, Briere J, et al. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997; 89: 128-134.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
8. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1027-1029.
9. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320-328.
10. Lasho TL, Mesa R, Gilliland DG, et al. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005; 130: 797-799.
11. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005; 280: 22788-22792.
12. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
13. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
14. Sattler M, Walz C, Crowley BJ, et al. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood 2006; 107: 1237-1238.
15. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes: Introduction. IARC Press: Lyon, 2001.
16. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
17. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236.
18. Campbell PJ, Scott LM, Baxter EJ, et al. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med 2006; 125: 253-264.